Form 4: Omeros Director Peter Demopulos Receives Annual Stock Option Grant

Omeros Corporation's Director, Peter A. Demopulos MD, was granted an option to purchase 15,000 shares of common stock at an exercise price of $3.2 per share, pursuant to the company's non-employee director compensation policy.

Summary

• Peter A. Demopulos MD, a Director of Omeros Corporation (OMER), was granted an option to purchase 15,000 shares of common stock.
• The grant occurred on June 27, 2025, in conjunction with the annual meeting of shareholders.
• The exercise price for these options is $3.2 per share.
• The options were granted under Omeros Corporation's non-employee director compensation policy.
• The options will fully vest and become exercisable on the day before the 2026 annual meeting of shareholders, provided Demopulos continues to serve as a director.
• The expiration date for these options is June 27, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine, positive event of a director receiving equity compensation, which aligns interests. There are no negative disclosures or red flags. The score reflects a neutral to slightly positive sentiment as it's a standard compensation event.

Positives

• The grant of stock options aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases.
• The compensation policy for non-employee directors provides a clear and established framework for equity awards, promoting transparency and consistency.

Risks

• The vesting of the stock options is contingent upon the director's continued service, meaning the options could be forfeited if service ceases before the vesting date.
• The value of the options is dependent on the future stock price of Omeros Corporation exceeding the $3.2 exercise price; if the stock price remains below this, the options may hold no intrinsic value.

Future Outlook

The stock option grant indicates a continued commitment to retaining and incentivizing non-employee directors through equity compensation, aligning their long-term interests with the company's performance and future growth.

Management Comments

• The stock option award was granted in conjunction with the annual meeting of shareholders held on June 27, 2025, pursuant to Omeros Corporation's non-employee director compensation policy.

Industry Context

This transaction is a routine insider filing common in the biotechnology and pharmaceutical industries, where equity compensation is a standard practice to attract and retain experienced board members. It reflects a typical mechanism for aligning director incentives with long-term shareholder value in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice across the biotechnology and pharmaceutical sectors, similar to companies like Amgen (AMGN) or Gilead Sciences (GILD), which also use equity-based compensation to align director interests with company performance.
• The specific number of options (15,000) and the exercise price ($3.2) are specific to Omeros's compensation policy and current valuation, and would need to be compared against peer companies of similar market capitalization and stage of development to assess competitiveness.
• The vesting schedule, contingent on continued service, is a standard retention mechanism seen in director compensation plans across various industries.

Corporate Governance

Related Party Transactions

• Grant of 15,000 stock options to Peter A. Demopulos MD, a non-employee director, as part of the company's standard director compensation policy.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, as the options gain value if the stock price increases. It represents a form of non-cash compensation that can reduce cash outlays for director fees.

Next Steps

• Continued service of Peter A. Demopulos MD as a director through the 2026 annual meeting for the options to fully vest.
• Potential exercise of the options by the director after vesting and before the expiration date, subject to market conditions.

Key Dates

Keywords

Omeros Corporation, OMER, Form 4, Stock Option, Director Compensation, Equity Grant, Insider Transaction, Peter A. Demopulos